RE: Slow5 Feb 2026 21:59
I do think the 2025 AGM update was wholly disingenuous when it came to "we've got great news from our phase 1 clinical trial."
For those that had forgotten, plus the BoD, they released the following RNS on 1st July 2024(!). A successful clinical trial was conducted in 2023 and 2024. 2025 was all about clicking send on the final report - it's hardly a great achievement for the year.
2025 was the year of the failed tox study. They took back 737 and have done bu***** all with it.
Let's face - 2025 was not a year to be proud of.
RNS, 1st July 2024:
Positive Data from SDC-1801 Phase 1 Clinical Trial
Cambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce positive topline data from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases.
Following the dosing of the final cohort in the Multiple Ascending Dose stage of the trial, and review of the initial data by the Safety Review Committee, the Company reports that:
· Blood plasma levels of SDC-1801 significantly in excess of the predicted therapeutic exposure were achieved, with a half-life of between 17 and 20 hours observed, which suggests that once-daily dosing will be possible*
· No deaths or serious adverse events due to SDC-1801 were reported
· Although data remains blinded, there appear to be no significant changes in blood cell counts or increases in serum creatinine levels, which may be dose limiting side-effects of brepocitinib, currently the most advanced TYK2/JAK1 dual inhibitor
*Half-life is an estimation of the time it takes for an initial concentration of SDC-1801 to be reduced by half in the body.
The Company expects that further data, unblinded from drug/placebo recipients, including details of any mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, will be available in Q3 2024.